Long-Term Safety of Adalimumab Reviewed

Burmester and colleagues have published their review of the long-term outcomes and safety issues with the TNF inhibitor, adalimumab (ADA). The analysis included…

Adalimumab Approved for Uveitis

Autoimmune ophthalmic disease is a frequent challenge to rheumatologists from both a diagnostic and therapeutic perspective. Approved therapies are limited and…

New mode of action for HUMIRA in rheumatoid arthritis patients

Researchers have discovered that the widely used antiinflammatory drug HUMIRA doesn't just work by inhibiting its target protein, TNF, but by enhancing a particular function of TNF in rheumatoid arthritis patients. The study may help explain the divergent efficacies of different TNF-targeting drugs.

Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF–TNF-RII binding in rheumatoid arthritis

The interplay between inflammatory and regulatory pathways orchestrates an effective immune response that provides protection from pathogens while limiting injury to host tissue. Tumor necrosis factor (TNF) is a pivotal inflammatory cytokine, but there is conflicting evidence as to whether it boosts...

Comments are closed.